Boccafoschi 1983.

Study characteristics
Methods	Study design: double‐blind, controlled clinical trial Study dates: not available Setting: outpatient, single center and national Country: Italy
Participants	Inclusion criteria: not available Exclusion criteria: not available Sample size: 22 randomized participants Age (years): Group 1 mean (range): 68 (55 to 80) Group 2 mean (range): 68 (54 to 78) IPSS score (baseline): not available Prostate size: not available
Interventions	Group 1 (n = 11): Permixon 160 mg, 2 capsules orally (1 in the morning and the other in the evening) for 60 days (total dose per day: 320 mg) Group 2 (n = 11): placebo 2 capsules orally (1 in the morning and the other in the evening) for 60 days Co‐interventions: none
Outcomes	Adverse events How measured: not described Time points measured: 60 days Time points reported: 60 days Subgroups: none Other outcomes measured in the trial: dysuria, nocturia, and urinary frequency
Notes	Funding: not specified Conflicts of interest: not specified